GALECTIN THERAPEUTICS INC.

(GALT)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
1.280 USD   -3.03%
05/17HC Wainwright Adjusts Price Target on Galectin Therapeutics to $11 From $14, Reiterates Buy Rating
MT
05/16Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
AQ
05/16GALECTIN THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société GALECTIN THERAPEUTICS INC.
05/16Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 an..
AQ
05/16GALECTIN THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition ..
AQ
04/14Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitor..
AQ
04/14GALECTIN THERAPEUTICS : Reports the Positive Outcome of the First Data and Safety Monitori..
PU
04/14GALECTIN THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
03/31GALECTIN THERAPEUTICS : Reports 2021 Financial Results and Provides Business Update - Form..
PU
03/31Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update
AQ
03/31GALECTIN THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition ..
AQ
01/06Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference
AQ
2021Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chair..
AQ
2021GALECTIN THERAPEUTICS : Announces Closing of $10 Million in Debt Financing from Its Chairm..
PU
2021GALECTIN THERAPEUTICS INC : Entry into a Material Definitive Agreement, Creation of a Dire..
AQ
2021Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial an..
AQ
2021GALECTIN THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021GALECTIN THERAPEUTICS : Thanks Kevin - Form 8-K
PU
2021GALECTIN THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2021GALECTIN THERAPEUTICS : Reports Financial Results for the Quarter Ended September 30, 2021..
PU
2021Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 202..
GL
2021GALECTIN THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition ..
AQ
2021Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting 2021, Ho..
AQ
2021UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver M..
GL
2021UPDATE – Galectin Therapeutics to Present Six Scientific Abstracts at The Liver M..
GL
2021Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting 2021,..
AQ
2021Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting&trade..
AQ
2021GALECTIN THERAPEUTICS : to Participate in the H.C. Wainwright 5th Annual NASH Investor Con..
AQ
2021UPDATE : Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Inves..
GL
2021UPDATE : Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Inves..
GL
2021GALECTIN THERAPEUTICS : to Participate in the H.C. Wainwright 23rd Annual Global Investmen..
AQ
2021GALECTIN THERAPEUTICS : Announces $20 Million Convertible Debt Financing from Its Chairman..
PU
2021GALECTIN THERAPEUTICS : Announces $20 Million Convertible Debt Financing from Its Chairman..
AQ
2021GALECTIN THERAPEUTICS INC : Entry into a Material Definitive Agreement, Creation of a Dire..
AQ
2021GALECTIN THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2021GALECTIN THERAPEUTICS : Presentation for H.C. Wainwright 23rd Annual Global Investment Con..
PU
2021Galectin Therapeutics, Inc. to Participate in the H.C. Wainwright 23rd Annual Global In..
GL
2021GALECTIN THERAPEUTICS : Strengthens Leadership Team with Strategic Hires to Advance Progra..
AQ
2021GALECTIN THERAPEUTICS : Considering options for a Combination Cancer Immunotherapy trial b..
PU
2021Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, an..
GL
2021GALECTIN THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
2021GALECTIN THERAPEUTICS : Regulation FD Disclosure (Form 8-K)
PU
2021GALECTIN THERAPEUTICS INC : Regulation FD Disclosure (form 8-K)
AQ
2021GALECTIN THERAPEUTICS : Announces Positive Top-Line Results from a Phase 1b Clinical Trial..
AQ
2021GALECTIN THERAPEUTICS INC : Financial Statements and Exhibits (form 8-K)
AQ
2021GALECTIN THERAPEUTICS : Announces Positive Top-Line Results from a Phase 1b Clinical Trial..
AQ
2021GALECTIN THERAPEUTICS : Reports Financial Results for the Quarter Ended March 31, 2021, an..
AQ
2021GALECTIN THERAPEUTICS : Reports Financial Results for the Quarter Ended March 31, 2021, an..
PU
2021GALECTIN THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
2021Galectin Therapeutics to Present at 4th Global NASH Congress
GL
2021GALECTIN THERAPEUTICS : World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin The..
AQ
2021GALECTIN THERAPEUTICS : Thinking about buying stock in Westport Fuel Systems, Galectin The..
PR
2021GALECTIN THERAPEUTICS : World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin The..
AQ
2021GALECTIN THERAPEUTICS INC : Entry into a Material Definitive Agreement, Creation of a Dire..
AQ
2021GALECTIN THERAPEUTICS : Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Res..
AQ
2021Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapec..
GL
2021Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physi..
GL
2021Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Updat..
GL
2021GALECTIN THERAPEUTICS : Corporate Presentation MARCH 2021.pdf
PU
2021GALECTIN THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2021GALECTIN THERAPEUTICS : OncoImmunology Publishes Pre-clinical Research Showing Galectin Th..
AQ
2021GALECTIN THERAPEUTICS : to Present at H.C. Wainwright Global Life Sciences Conference
AQ
2021Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
GL
2020GALECTIN THERAPEUTICS : 4th Annual Digital NASH Summit Presentation
PU
2020GALECTIN THERAPEUTICS : to Present at the 4th Annual Digital NASH Summit on December 17, 2..
AQ
2020Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on Decembe..
GL
2020GALECTIN THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2020GALECTIN THERAPEUTICS : Transcript of December 3, 2020, GALT Annual Meeting
PU
2020Galectin Therapeutics Inc. Recaps Results of Annual Meeting of Stockholders Presentatio..
GL
2020GALECTIN THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2020Galectin Therapeutics to Webcast Corporate Update on December 3, 2020 after Annual Meet..
GL
2020GALECTIN THERAPEUTICS : Provides Business Update and Reports Financial Results for the Qua..
AQ
2020GALECTIN THERAPEUTICS : Provides Business Update And Reports Financial Results for the Qua..
AQ
2020Galectin Therapeutics Provides Business Update And Reports Financial Results for the Qu..
GL
2020GALECTIN THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Re..
AQ
2020GALECTIN THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
2020EMERGINGGROWTH.COM : EmergingGrowth.com Reports on Why Galectin Therapeutics is Due for a ..
AQ
2020GALECTIN THERAPEUTICS : Investor Conference Call and Webinar Taking Place Today
AQ
1  2  3  4Next
Upcoming event on GALECTIN THERAPEUTICS INC.